Key result
Intermittent nitroprusside linked to ~66% lower odds of death or urgent transplant versus dobutamine.
Why the study?
Does chronic intermittent nitroprusside infusion improve clinical outcomes compared to dobutamine in patients with end-stage heart failure awaiting heart transplantation?
Observational (n=113)
Does chronic intermittent nitroprusside infusion improve clinical outcomes compared to dobutamine in patients with end-stage heart failure awaiting heart transplantation?
Odds Ratio: 0.34 (95% CI 0.14–0.8)
Absolute Event Rate: 51% vs 84%
p-value: p=<0.01
In patients with end-stage heart failure awaiting transplantation, chronic intermittent nitroprusside infusion is associated with lower mortality and reduced need for urgent transplantation compared to dobutamine.
No takes yet. Share an insight, caveat, or question.
May support nitroprusside over dobutamine in transplant candidates; leaves open randomized confirmation before practice change.
Capomolla et al. (2001) conducted an observational in Advanced heart failure awaiting heart transplantation (n=113). Nitroprusside vs. Dobutamine was evaluated on Combined end-point of mortality or heart transplantation in status one (OR 0.34, 95% CI 0.14-0.80, p=<0.01). Chronic intermittent nitroprusside infusion was associated with a lower rate of mortality or urgent heart transplantation compared to dobutamine (51% vs. 84%; OR 0.34; 95% CI 0.14-0.80; P<0.01).
Synapse has enriched one closely related paper. Consider it for comparative context: